Haematology 2018

Trial Endpoints Primary • Global assessment of overall response of the combination of pembrolizumab plus radiotherapy at 24 weeks Secondary • Response after 12 weeks of pembrolizumab • Change (improvement) in response with combinational RT • Duration of response for the combination treatment/time to next treatment • Abscopal effect (measured by ‘shrinking’ of 5 pre-defined lesions which have not been irradiated using a 5 point score). • Safety • Progression-Free & Overall survival